Genetic Signatures
Market Cap
AU$166.5m
Last Updated
2020/02/17 10:47 UTC
Data Sources
Company Financials +
Executive Summary
Genetic Signatures Limited operates as a molecular diagnostic (MDx) company in North America and Australia.
Rewards
Risk Analysis
Snowflake Analysis
Flawless balance sheet with high growth potential.
Share Price & News
How has Genetic Signatures's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: GSS has not had significant price volatility in the past 3 months.
Market Performance
7 Day Return
4.0%
GSS
-2.0%
AU Life Sciences
1.5%
AU Market
1 Year Return
24.5%
GSS
11.9%
AU Life Sciences
15.6%
AU Market
Return vs Industry: GSS exceeded the Australian Life Sciences industry which returned 12.5% over the past year.
Return vs Market: GSS exceeded the Australian Market which returned 16.1% over the past year.
Shareholder returns
| GSS | Industry | Market | |
|---|---|---|---|
| 7 Day | 4.0% | -2.0% | 1.5% |
| 30 Day | 11.4% | -1.8% | 0.4% |
| 90 Day | 2.6% | 9.2% | 4.1% |
| 1 Year | 24.5%24.5% | 14.7%11.9% | 20.6%15.6% |
| 3 Year | 188.9%188.9% | -6.0%-14.3% | 37.1%18.7% |
| 5 Year | n/a | -61.2%-73.8% | 50.9%17.1% |
Price Volatility Vs. Market
How volatile is Genetic Signatures's share price compared to the market and industry in the last 5 years?
Simply Wall St News
14 hours ago | Simply Wall St
Have Insiders Been Selling Genetic Signatures Limited (ASX:GSS) Shares?3 weeks ago | Simply Wall St
Genetic Signatures Limited (ASX:GSS): Is Breakeven Near?1 month ago | Simply Wall St
Is Genetic Signatures Limited (ASX:GSS) Excessively Paying Its CEO?Valuation
Is Genetic Signatures undervalued compared to its fair value and its price relative to the market?
11.52x
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate GSS's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate GSS's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: GSS is unprofitable, so we can't compare its PE Ratio to the Life Sciences industry average.
PE vs Market: GSS is unprofitable, so we can't compare its PE Ratio to the Australian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate GSS's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: GSS is overvalued based on its PB Ratio (11.5x) compared to the AU Life Sciences industry average (9.1x).
Next Steps
Future Growth
How is Genetic Signatures forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
41.3%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: GSS is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.1%).
Earnings vs Market: GSS is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: GSS's is expected to become profitable in the next 3 years.
Revenue vs Market: GSS's revenue (37% per year) is forecast to grow faster than the Australian market (4.2% per year).
High Growth Revenue: GSS's revenue (37% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: GSS's Return on Equity is forecast to be low in 3 years time (0.6%).
Next Steps
Past Performance
How has Genetic Signatures performed over the past 5 years?
-7.9%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: GSS is currently unprofitable.
Growing Profit Margin: GSS is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: GSS is unprofitable, and losses have increased over the past 5 years at a rate of -7.9% per year.
Accelerating Growth: Unable to compare GSS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: GSS is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (14.5%).
Return on Equity
High ROE: GSS has a negative Return on Equity (-33.04%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Next Steps
Financial Health
How is Genetic Signatures's financial position?
Financial Position Analysis
Short Term Liabilities: GSS's short term assets (A$10.7M) exceed its short term liabilities (A$1.5M).
Long Term Liabilities: GSS's short term assets (A$10.7M) exceed its long term liabilities (A$19.3K).
Debt to Equity History and Analysis
Debt Level: GSS is debt free.
Reducing Debt: GSS had no debt 5 years ago.
Balance Sheet
Inventory Level: GSS has a high level of physical assets or inventory.
Debt Coverage by Assets: Insufficient data to determine if GSS's debt is covered by short term assets.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: GSS has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: GSS has sufficient cash runway for 1 years if free cash flow continues to reduce at historical rates of -8.9% each year.
Next Steps
Dividend
What is Genetic Signatures's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate GSS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate GSS's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if GSS's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if GSS's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of GSS's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
6.1yrs
Average management tenure
CEO
John Melki 0
9.1yrs
Tenure
AU$390,385
Compensation
Dr. John R. Melki, BSc, Ph.D. has been the Chief Executive Officer of Genetic Signatures Limited since 2011 and serves as its Managing Director and also served as its Senior Principal Research Scientist an ...
CEO Compensation Analysis
Compensation vs Market: John's total compensation ($USD262.30K) is about average for companies of similar size in the Australian market ($USD254.67K).
Compensation vs Earnings: John's compensation has increased whilst the company is unprofitable.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| MD, CEO & Executive Director | 9.1yrs | AU$390.39k | 0.77% A$1.3m | |
| CFO & Company Secretary | 1.3yrs | AU$244.22k | no data | |
| Executive Director of US Operations & Executive Director | 5.8yrs | AU$177.42k | 0.45% A$755.6k | |
| Founder & Chairman Emeritus | 0yrs | no data | 0.059% A$98.9k | |
| Chief Scientific Officer | 19.1yrs | AU$308.55k | 0.61% A$1.0m | |
| US Market Consultant | 3.6yrs | AU$4.30k | no data |
6.1yrs
Average Tenure
Experienced Management: GSS's management team is seasoned and experienced (6.1 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| MD, CEO & Executive Director | 9.1yrs | AU$390.39k | 0.77% A$1.3m | |
| Executive Director of US Operations & Executive Director | 5.8yrs | AU$177.42k | 0.45% A$755.6k | |
| Founder & Chairman Emeritus | 0yrs | no data | 0.059% A$98.9k | |
| Non-Independent Executive Director | 4.4yrs | AU$56.21k | 0.17% A$280.8k | |
| Independent Non-Executive Chairman | 12.1yrs | AU$75.42k | 1.42% A$2.4m |
5.8yrs
Average Tenure
Experienced Board: GSS's board of directors are considered experienced (5.8 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: GSS insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Genetic Signatures Limited's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Genetic Signatures Limited
- Ticker: GSS
- Exchange: ASX
- Founded: 2001
- Industry: Life Sciences Tools and Services
- Sector: Pharmaceuticals & Biotech
- Market Cap: AU$166.525m
- Shares outstanding: 142.33m
- Website: https://www.geneticsignatures.com
Number of Employees
Location
- Genetic Signatures Limited
- 7 Eliza Street
- Newtown
- Sydney
- New South Wales
- 2042
- Australia
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| GSS | ASX (Australian Securities Exchange) | Yes | Ordinary Shares | AU | AUD | Mar 2015 |
| GSS | CHIA (Chi-X Australia) | Yes | Ordinary Shares | AU | AUD | Mar 2015 |
Biography
Genetic Signatures Limited operates as a molecular diagnostic (MDx) company in North America and Australia. The company designs and manufactures a suite of real-time polymerase chain reaction based products for detection of infectious diseases under EasyScreen brand name. It also provides MDx 3Base platform technology that enables hospital and pathology laboratories to screen for a range of infectious pathogens. In addition, the company offers MethylEasy for DNA bisulphite modification of histones for screening of cancer and embryonic development, as well as use in stem cell technologies. Genetic Signatures Limited was founded in 2001 and is headquartered in Sydney, Australia.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/02/17 10:47 |
| End of Day Share Price | 2020/02/17 00:00 |
| Earnings | 2019/06/30 |
| Annual Earnings | 2019/06/30 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.